Related Experiment Videos
[Gene therapy in lysosomal diseases]
P Moullier1, A Salvetti, D Bohl
1Laboratoire Rétrovirus et Transfert génétique, Institut Pasteur, Paris, France.
Comptes Rendus Des Seances De La Societe De Biologie Et De Ses Filiales
|January 1, 1996
Summary
This study proposes enzyme replacement therapy for lysosomal diseases using genetically modified cells. Autologous fibroblast implants stably secreted human glucuronidase, showing promise for treating Hurler's syndrome.
Area of Science:
- Biochemistry
- Genetics
- Cell Biology
Context:
- Lysosomal diseases result from enzyme deficiencies.
- Enzyme replacement therapy is a proposed treatment strategy.
- Understanding enzyme secretion and recapture is crucial.
Purpose:
- To develop a method for treating lysosomal diseases via enzyme replacement.
- To achieve systemic distribution of missing enzymes using genetically modified cells.
- To demonstrate the feasibility of reimplanting genetically modified fibroblasts.
Summary:
- A procedure for reimplanting genetically modified autologous fibroblasts was developed.
- Stable secretion of human glucuronidase by these fibroblasts was achieved in animal models.
- This approach is applicable to Hurler's syndrome using alpha-L-iduronidase gene transfer.
Impact:
- This method offers a potential treatment for lysosomal storage disorders.
- It enables the production and systemic distribution of deficient enzymes.
- The approach paves the way for autologous cell-based enzyme therapies.